Stocks To Cash In On The $35 Billion NASH Dash
Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for…
Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for…
Why invest in a single factor ETF when you can invest in a multifactor ETF? As the author of today’s article notes, “Multifactor funds imitate…
Against a backdrop of increased market volatility, interest in “safe haven” assets – including precious metals – is increasing. However, today’s article outlines how, “Despite…
The biggest – and seemingly indisputable – takeaway from the first three months of 2018, according to the author of today’s article? Volatility is back.…
Companies with high levels of floating rate debt have struggled as interest rates have ticked up – but today’s article highlights “a potentially high return,…
Of the exchange-traded fund highlighted in today’s article, the author declares that “Quite simply, this is a fund that has a place in just about…
When setting up your trades, how do you go about determining your exit target? The author of today’s article advises that “While using the charts…
Not all dividend champions are created equal. In order to identify dividend champions worthy of further research, the author of today’s article screened the list…
When it comes to growth investors, the authors of today’s article state “We want high-quality growth stocks in our portfolios that can stand the test…
When it comes to the relatively recent advent of mutual funds and exchange-traded funds focused on the cannabis industry, the author of today’s article states,…